Semaglutide associated with weight loss in people without diabetes!

The findings of a study issued in ‘Endocrine, Metabolic and Immune Disorders Drug Target’ showed safety and efficacy of Semaglutide for weight loss in non-diabetic subjects.

Cai-E Song and researchers enrolled 84 non-diabetic subjects from January 1, 2022 to June 30, 2022 who used Semaglutide (glucagon-like peptide-1 (GLP-1) as a weight loss medication. These subjects were compared pre- and 12 weeks’ post-treatment for body weight, body mass index (BMI), waist circumstance, blood pressure, fasting blood glucose, pulse and body composition (body fat ratio, skeletal muscle and visceral fat area). Semaglutide was administered in doses of 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg subcutaneously once a week for a duration of 12 weeks.

As per the results, all the subjects lost an average of 5.91 ± 3.37 kg, which represents a 6.15 ± 4.28% reduction from the baseline weight, along with significant reductions in visceral fat area along with slightly lower blood pressure.

The majority of adverse reactions were mild characterized by episodes of diarrhea, nausea and vomiting that generally resolved within a day or two. No significant adverse reactions, such as hypotension or hypoglycemia, were reported.